{"preliminary_commentary":{"by_channel":{"podcast":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["abemaciclib"]],"indication":"heavily treated metastatic castration-resistant prostate cancer","name":"CYCLONE 1","nct_id":"NCT04408924","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cyclone-1-nct04408924. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CYCLONE 1","arms":[{"description":"Participants received 200 mg abemaciclib administered orally twice daily on a continuous dosing schedule (28-day cycle) until symptomatic and/or radiographic progression, unacceptable toxicity, or until another discontinuation criterion is met.","label":"200 milligram (mg) Abemaciclib Twice Daily","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-06-02","type":"ACTUAL"},"conditions":["Metastatic Castration-Resistant Prostate Cancer"],"enrollment":{"count":44,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Abemaciclib","otherNames":["LY2835219"],"type":"DRUG"}],"last_update":"2024-06-25","lead_sponsor":"Eli Lilly and Company","official_title":"CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-04-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])","timeFrame":"From Date of First Dose until Objective Progression (Up To 12.8 Months)"}],"references":[],"start_date":{"date":"2021-01-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04408924"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cyclone-1-nct04408924"}